Literature DB >> 33665376

Evaluation of the performance of QuantiFERON®-TB Gold plus test in active tuberculosis patients.

Cengiz Çavuşoğlu1, Melike Yaşar-Duman1, Mehmet Sezai Taşbakan2, Meltem Işıkgöz-Taşbakan3, Mehmet Nurullah Orman4.   

Abstract

The aim was to evaluate the sensitivity and the possible factors affecting the sensitivity of the QuantiFERON®-TB Gold Plus (QFT-Plus) assay in culture-positive active TB (Tuberculosis) patients, to investigate the possible causes of negative and indeterminate results in active TB patients, and to compare the QFT-Plus results of active TB patients and latent tuberculosis infection (LTBI) cases. The QFT-Plus assay was performed in 46 active TB patients and 64 LTBI. The sensitivity of the test was found as 79.5% in all culture-positive patients, 72.7% in the immunocompromised patients, and 86.4% in the non-immunocompromised patients. Compared to active TB, individuals with LTBI had a lower T-cell response and lower IFN-ɣ concentrations. It was determined that the immunocompromisation reduced the sensitivity of the test and the secreted IFN-ɣ concentrations and increased the indeterminate results in patients with active TB. There was no difference in secreted IFN-ɣ concentrations between M. tuberculosis clones, but higher IFN-ɣ concentrations in patients infected with M. tuberculosis strains compared to patients infected with zoonotic strains. Compared with active TB, response to "only to TB2" was significantly higher in LTBI. In conclusion, it was concluded that TB2 tube increased sensitivity in LTBI but may not contribute to sensitivity in active TB.
© 2021 The Authors. Published by Elsevier Ltd.

Entities:  

Keywords:  Active TB; LTBI; QuantiFERON TB Gold Plus; Spoligotyping

Year:  2021        PMID: 33665376      PMCID: PMC7900580          DOI: 10.1016/j.jctube.2021.100223

Source DB:  PubMed          Journal:  J Clin Tuberc Other Mycobact Dis        ISSN: 2405-5794


  30 in total

1.  First independent evaluation of QuantiFERON-TB Plus performance.

Authors:  Lucia Barcellini; Emanuele Borroni; James Brown; Enrico Brunetti; Luigi Codecasa; Federica Cugnata; Paola Dal Monte; Clelia Di Serio; Delia Goletti; Giulia Lombardi; Marc Lipman; Paola M V Rancoita; Marina Tadolini; Daniela M Cirillo
Journal:  Eur Respir J       Date:  2016-02-11       Impact factor: 16.671

2.  CD4+ T cell-dependent IFN-γ production by CD8+ effector T cells in Mycobacterium tuberculosis infection.

Authors:  Tyler D Bold; Joel D Ernst
Journal:  J Immunol       Date:  2012-07-25       Impact factor: 5.422

3.  Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis.

Authors:  E Petruccioli; V Vanini; T Chiacchio; G Cuzzi; D M Cirillo; F Palmieri; G Ippolito; D Goletti
Journal:  Tuberculosis (Edinb)       Date:  2017-06-27       Impact factor: 3.131

4.  Equal sensitivity of the new generation QuantiFERON-TB Gold plus in direct comparison with the previous test version QuantiFERON-TB Gold IT.

Authors:  H Hoffmann; K Avsar; R Göres; S-C Mavi; S Hofmann-Thiel
Journal:  Clin Microbiol Infect       Date:  2016-05-13       Impact factor: 8.067

Review 5.  Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis.

Authors:  John Z Metcalfe; Charles K Everett; Karen R Steingart; Adithya Cattamanchi; Laurence Huang; Philip C Hopewell; Madhukar Pai
Journal:  J Infect Dis       Date:  2011-11-15       Impact factor: 5.226

6.  Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube Interferon Gamma Release Assays in Patients at Risk for Tuberculosis and in Health Care Workers.

Authors:  Elitza S Theel; Heather Hilgart; Margaret Breen-Lyles; Kevin McCoy; Rhiannon Flury; Laura E Breeher; John Wilson; Irene G Sia; Jennifer A Whitaker; Jeremy Clain; Timothy R Aksamit; Patricio Escalante
Journal:  J Clin Microbiol       Date:  2018-06-25       Impact factor: 5.948

7.  First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus.

Authors:  Elisa Petruccioli; Teresa Chiacchio; Ilaria Pepponi; Valentina Vanini; Rocco Urso; Gilda Cuzzi; Lucia Barcellini; Daniela Maria Cirillo; Fabrizio Palmieri; Giuseppe Ippolito; Delia Goletti
Journal:  J Infect       Date:  2016-10-04       Impact factor: 6.072

8.  Comparison of QFT-Plus and QFT-GIT tests for diagnosis of M. tuberculosis infection in immunocompetent Korean subjects.

Authors:  Ji Young Hong; So Yeong Park; Ahreum Kim; Sang-Nae Cho; Yun-Gyoung Hur
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

Review 9.  The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.

Authors:  Rein M G J Houben; Peter J Dodd
Journal:  PLoS Med       Date:  2016-10-25       Impact factor: 11.069

10.  Interferon gamma release assays for the diagnosis of latent TB infection in HIV-infected individuals in a low TB burden country.

Authors:  Clíona Ní Cheallaigh; Ian Fitzgerald; Jacinta Grace; Gurmit Jagjit Singh; Nahla El-Eraki; Noel Gibbons; Joseph Keane; Thomas R Rogers; Susan Clarke; Colm Bergin
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.